We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IQV has a decent earnings surprise history, having surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 1.6%.
The Zacks Consensus Estimate for revenues is kept at $4.2 billion, suggesting 7.2% year-over-year growth.
The consensus mark for the Technology & Analytics (TAS) segment’s revenues is pinned at $1.8 billion, indicating a 6.9% rise from the year-ago quarter’s actual. The sustained momentum from drug launches and strength in the broader commercial portfolio are likely to have fueled this segment’s revenues.
For Research & Development, the Zacks Consensus Estimate for revenues is kept at $2.3 billion, implying a 7.7% year-over-year increase. The company saw 20% growth in Request for Proposals in the third quarter of 2025, indicating a robust pipeline of future clinical work that is expected to have benefited this segment in the fourth quarter.
The consensus estimate for the Contract Sales & Medical segment’s revenues is pegged at $193.2 million, indicating a 9.1% increase from the year-ago quarter’s actual. This growth is anticipated to have been facilitated by large multi-year engagements spanning across therapies and geographies.
Based on geography, the Zacks Consensus Estimate for revenues from the Americas is set at $2 billion, implying an 8.1% uptick from the year-ago quarter’s reported number. For Europe and Asia, the consensus estimate for revenues is kept at $1.3 billion, suggesting a 3.8% year-over-year rise. The consensus mark for Asia-Pacific revenues is pegged at $882.6 million, increasing 9.4% from the year-ago quarter.
The consensus estimate for earnings per share is kept at $3.4, hinting at 9% year-over-year growth.
What Our Model Says About IQV
Our proven model does not conclusively predict an earnings beat for IQVIA this time around. The combination of a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.
Here are a few stocks from the broader Medical sector, which, according to our model, have the right combination of elements to beat on earnings this time around.
Amneal Pharmaceuticals (AMRX - Free Report) : The Zacks Consensus Estimate for the company’s fourth-quarter 2025 revenues is pegged at $814.1 million, indicating 11.4% year-over-year growth. For earnings, the consensus mark is pinned at 17 cents per share, suggesting a 41.7% jump from the year-ago quarter’s reported figure. The company beat the consensus estimate in three of the past four quarters and missed once, with an average surprise of 22.4%.
AMRX carries an Earnings ESP of +11.77% and a Zacks Rank of 2 at present. The company is scheduled to declare fourth-quarter 2025 results on Feb. 27.
Bausch Health (BHC - Free Report) : The Zacks Consensus Estimate for the company’s fourth-quarter 2025 revenues is pinned at $2.7 billion, suggesting growth of 5.7% from the year-ago quarter’s actual. For earnings, the consensus mark is set at $1.21 per share, hinting at a 5.2% rise from the year-ago quarter’s reported figure. BHC beat the consensus estimate for earnings in two of the four quarters and missed twice, with an average negative surprise of 6.3%.
BHC has an Earnings ESP of +0.69% and a Zacks Rank of 3 at present. The company is scheduled to declare fourth-quarter 2025 results on Feb. 18.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
IQVIA Set to Report Q4 Earnings: Here's What You Should Know
Key Takeaways
IQVIA Holdings Inc. (IQV - Free Report) is set to release fourth-quarter 2025 results on Feb. 5, before market open.
IQV has a decent earnings surprise history, having surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 1.6%.
IQVIA Holdings Inc. Price and EPS Surprise
IQVIA Holdings Inc. price-eps-surprise | IQVIA Holdings Inc. Quote
IQVIA’s Q4 Expectations
The Zacks Consensus Estimate for revenues is kept at $4.2 billion, suggesting 7.2% year-over-year growth.
The consensus mark for the Technology & Analytics (TAS) segment’s revenues is pinned at $1.8 billion, indicating a 6.9% rise from the year-ago quarter’s actual. The sustained momentum from drug launches and strength in the broader commercial portfolio are likely to have fueled this segment’s revenues.
For Research & Development, the Zacks Consensus Estimate for revenues is kept at $2.3 billion, implying a 7.7% year-over-year increase. The company saw 20% growth in Request for Proposals in the third quarter of 2025, indicating a robust pipeline of future clinical work that is expected to have benefited this segment in the fourth quarter.
The consensus estimate for the Contract Sales & Medical segment’s revenues is pegged at $193.2 million, indicating a 9.1% increase from the year-ago quarter’s actual. This growth is anticipated to have been facilitated by large multi-year engagements spanning across therapies and geographies.
Based on geography, the Zacks Consensus Estimate for revenues from the Americas is set at $2 billion, implying an 8.1% uptick from the year-ago quarter’s reported number. For Europe and Asia, the consensus estimate for revenues is kept at $1.3 billion, suggesting a 3.8% year-over-year rise. The consensus mark for Asia-Pacific revenues is pegged at $882.6 million, increasing 9.4% from the year-ago quarter.
The consensus estimate for earnings per share is kept at $3.4, hinting at 9% year-over-year growth.
What Our Model Says About IQV
Our proven model does not conclusively predict an earnings beat for IQVIA this time around. The combination of a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.
IQV has an Earnings ESP of 0.00% and a Zacks Rank of 2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to Consider
Here are a few stocks from the broader Medical sector, which, according to our model, have the right combination of elements to beat on earnings this time around.
Amneal Pharmaceuticals (AMRX - Free Report) : The Zacks Consensus Estimate for the company’s fourth-quarter 2025 revenues is pegged at $814.1 million, indicating 11.4% year-over-year growth. For earnings, the consensus mark is pinned at 17 cents per share, suggesting a 41.7% jump from the year-ago quarter’s reported figure. The company beat the consensus estimate in three of the past four quarters and missed once, with an average surprise of 22.4%.
AMRX carries an Earnings ESP of +11.77% and a Zacks Rank of 2 at present. The company is scheduled to declare fourth-quarter 2025 results on Feb. 27.
Bausch Health (BHC - Free Report) : The Zacks Consensus Estimate for the company’s fourth-quarter 2025 revenues is pinned at $2.7 billion, suggesting growth of 5.7% from the year-ago quarter’s actual. For earnings, the consensus mark is set at $1.21 per share, hinting at a 5.2% rise from the year-ago quarter’s reported figure. BHC beat the consensus estimate for earnings in two of the four quarters and missed twice, with an average negative surprise of 6.3%.
BHC has an Earnings ESP of +0.69% and a Zacks Rank of 3 at present. The company is scheduled to declare fourth-quarter 2025 results on Feb. 18.